Avadel Pharmaceuticals (AVDL) announced that yesterday, the U.S. District Court for the District of Columbia ruled in favor of the Food and Drug Administration, FDA, in a suit brought by Jazz Pharmaceuticals (JAZZ) under the Administrative Procedure Act regarding the FDA’s approval of LUMRYZ, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy. With this ruling, the approval of LUMRYZ is upheld based on the FDA’s determination that LUMRYZ is clinically superior to Jazz’s twice-nightly oxybate products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals, nference announce publication on sleep advances
- Avadel Pharmaceuticals Gains FDA Approval for LUMRYZ
- Avadel Pharmaceuticals announces FDA approval of sNDA for LUMRYZ
- Avadel Pharmaceuticals call volume above normal and directionally bullish
- Avadel Pharmaceuticals announces publication of data on LUMRYZ